Evidence map›Paper›PMID 39357980›Full record

ArticleJournal for immunotherapy of cancer2024

Cancer cell-specific PD-L1 expression is a predictor of poor outcome in patients with locally advanced oral cavity squamous cell carcinoma.

Minyu Wang, Lei Qin, Kevin Thia, Thu Nguyen, Sean MacDonald, Simone Belobrov, Sevastjan Kranz, David Goode, Joseph A Trapani, David Wiesenfeld and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Minyu WangCancer Immunology Research, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia paul.neeson@petermac.org Minyu.Wang@petermac.org.ORCID http://orcid.org/0000-0002-1051-5855
Lei QinSir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.
Kevin ThiaCancer Immunology Research, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Thu NguyenCancer Immunology Research, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Sean MacDonaldCancer Immunology Research, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Simone BelobrovMelbourne Dental School, The University of Melbourne, Melbourne, Victoria, Australia.
Sevastjan KranzDepartment of Pathology, The Royal Melbourne Hospital, Parkville, Victoria, Australia.
David GoodeSir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.
Joseph A TrapaniCancer Immunology Research, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
David WiesenfeldMelbourne Dental School, The University of Melbourne, Melbourne, Victoria, Australia.
Paul Joseph NeesonCancer Immunology Research, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia paul.neeson@petermac.org Minyu.Wang@petermac.org.ORCID http://orcid.org/0000-0002-2729-5887

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLocally advanced oral cavity squamous cell carcinoma (OCSCC) presents a significant clinical challenge despite being partially responsive to standard treatment modalities. This study investigates the prognostic implications of programmed death-ligand 1 (PD-L1) expression in these tumors, focusing on its association with treatment outcomes and the immune microenvironment.

methodsWe assessed tumor-infiltrating lymphocytes (TILs) in 132 patients with OCSCC to evaluate their impact on survival. Multiplex immunohistochemistry staining for CD3, CD68, CD11c, PD-L1, and P40 was used to explore correlations with clinical outcomes in patients with early-stage (n=22) and locally advanced (n=36) OCSCC. These initial findings were validated through differential gene expression analysis, gene set enrichment, and immune cell deconvolution in a The Cancer Genome Atlas cohort of 163 locally advanced OCSCC tumors. Additionally, single-cell RNA sequencing (scRNA-seq) on a smaller cohort (n=10) further characterized the PD-L1

resultsElevated PD-L1 expression was associated with poor outcomes in patients with locally advanced OCSCC undergoing standard adjuvant therapy, irrespective of "hot" or "cold" classification based on TILs assessment. PD-L1

conclusionOur findings underscore the prognostic significance of PD-L1 expression in locally advanced OCSCC, and unveil the complex interplay between PD-L1 expression, immune responses, and molecular pathways in the tumor microenvironment. This study provides insights that may inform future therapeutic strategies, including the possibility of tailored immunotherapeutic approaches for patients with PD-L1

Indexed as

B7-H1 AntigenLymphocytes, Tumor-InfiltratingMouth NeoplasmsTumor MicroenvironmentAdultAgedBiomarkers, TumorCarcinoma, Squamous CellFemaleHumansMaleMiddle AgedPrognosisSquamous Cell Carcinoma of Head and NeckB7-H1 AntigenBiomarkers, TumorCD274 protein, humanAdjuvantHead and Neck CancerImmune Checkpoint InhibitorRadiotherapy/RadioimmunotherapyTumor Microenvironment

Identifiers

PMID39357980
PMCPMC11448134

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.